Share-based Payment Arrangement, Expense of NEOGENOMICS INC from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NEOGENOMICS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • NEOGENOMICS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $10,305,000, a 22% increase year-over-year.
  • NEOGENOMICS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $41,602,000, a 30% increase year-over-year.
  • NEOGENOMICS INC annual Share-based Payment Arrangement, Expense for 2024 was $33,413,000, a 36% increase from 2023.
  • NEOGENOMICS INC annual Share-based Payment Arrangement, Expense for 2023 was $24,633,000, a 0.16% decline from 2022.
  • NEOGENOMICS INC annual Share-based Payment Arrangement, Expense for 2022 was $24,672,000, a 9.7% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NEOGENOMICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $41,602,000 $10,305,000 +$1,835,000 +22% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 $39,767,000 $12,215,000 +$3,374,000 +38% 01 Apr 2025 30 Jun 2025 10-Q 29 Jul 2025 2025 Q2
Q1 2025 $36,393,000 $10,754,000 +$2,980,000 +38% 01 Jan 2025 31 Mar 2025 10-Q 29 Apr 2025 2025 Q1
Q4 2024 $33,413,000 $8,328,000 +$1,338,000 +19% 01 Oct 2024 31 Dec 2024 10-K 18 Feb 2025 2024 FY
Q3 2024 $32,075,000 $8,470,000 +$1,290,000 +18% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 $30,785,000 $8,841,000 +$3,136,000 +55% 01 Apr 2024 30 Jun 2024 10-Q 29 Jul 2025 2025 Q2
Q1 2024 $27,649,000 $7,774,000 +$3,016,000 +63% 01 Jan 2024 31 Mar 2024 10-Q 29 Apr 2025 2025 Q1
Q4 2023 $24,633,000 $6,990,000 +$2,318,000 +50% 01 Oct 2023 31 Dec 2023 10-K 18 Feb 2025 2024 FY
Q3 2023 $22,315,000 $7,180,000 +$2,880,000 +67% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $19,435,000 $5,705,000 +$2,105,000 +58% 01 Apr 2023 30 Jun 2023 10-Q 30 Jul 2024 2024 Q2
Q1 2023 $17,330,000 $4,758,000 -$7,342,000 -61% 01 Jan 2023 31 Mar 2023 10-Q 30 Apr 2024 2024 Q1
Q4 2022 $24,672,000 $4,672,000 -$5,428,000 -54% 01 Oct 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
Q3 2022 $30,100,000 $4,300,000 -$900,000 -17% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $31,000,000 $3,600,000 -$900,000 -20% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $31,900,000 $12,100,000 +$9,400,000 +348% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $22,500,000 $10,100,000 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $5,200,000 +$2,500,000 +93% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $4,500,000 +$1,900,000 +73% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $2,700,000 +$500,000 +23% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q3 2020 $2,700,000 -$600,000 -18% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $2,600,000 +$300,000 +13% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $2,200,000 +$100,000 +4.8% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q3 2019 $3,300,000 +$2,200,000 +200% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $2,300,000 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $2,100,000 +$500,000 +31% 01 Jan 2019 31 Mar 2019 10-Q 29 Apr 2020 2020 Q1
Q3 2018 $1,100,000 -$1,700,000 -61% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q1 2018 $1,600,000 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q3 2017 $2,800,000 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q3 2015 $828,000 +$508,000 +159% 01 Jul 2015 30 Sep 2015 10-Q 06 Nov 2015 2015 Q3
Q2 2015 $508,000 +$351,000 +224% 01 Apr 2015 30 Jun 2015 10-Q 31 Jul 2015 2015 Q2
Q1 2015 $342,000 +$253,000 +284% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q1
Q3 2014 $320,000 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $157,000 01 Apr 2014 30 Jun 2014 10-Q 31 Jul 2015 2015 Q2
Q1 2014 $89,000 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1

NEOGENOMICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $33,413,000 +$8,780,000 +36% 01 Jan 2024 31 Dec 2024 10-K 18 Feb 2025 2024 FY
2023 $24,633,000 -$39,000 -0.16% 01 Jan 2023 31 Dec 2023 10-K 18 Feb 2025 2024 FY
2022 $24,672,000 +$2,172,000 +9.7% 01 Jan 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
2021 $22,500,000 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2012 $575,000 +$290,000 +102% 01 Jan 2012 31 Dec 2012 10-K 21 Feb 2013 2012 FY
2011 $285,000 01 Jan 2011 31 Dec 2011 10-K 21 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.